Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Mell LK, Shen H, Nguyen-Tan PF, Rosenthal DI, Zakeri K, Vitzthum LK, Frank SJ, Schiff PB, Trotti A, Bonner JA, Jones CU, Yom SS, Thorstad WL, Wong S, Shenouda G, Ridge JA, Zhang QE, Le QT.

Clin Cancer Res. 2019 Aug 16. pii: clincanres.1832.2019. doi: 10.1158/1078-0432.CCR-19-1832. [Epub ahead of print]

PMID:
31420360
2.

Cost in perspective: direct assessment of American market acceptability of Co-60 in gynecologic high-dose-rate brachytherapy and contrast with experience abroad.

Mailhot Vega RB Jr, Barbee D, Talcott W, Duckworth T, Shah BA, Ishaq OF, Small C, Yeung AR, Perez CA, Schiff PB, Ginsburg O, Small W, Abdel-Wahab M, Bardales GS, Harkenrider M.

J Contemp Brachytherapy. 2018 Dec;10(6):503-509. doi: 10.5114/jcb.2018.79928. Epub 2018 Dec 28.

3.
4.

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H.

JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251.

5.

Dose dissonance in radiation oncology: Consensus needed when prescribing dose in radiation therapy.

Schiff PB.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):e579-e580. doi: 10.1016/j.prro.2017.04.018. Epub 2017 May 9. No abstract available.

PMID:
28666903
6.

A national survey of HDR source knowledge among practicing radiation oncologists and residents: Establishing a willingness-to-pay threshold for cobalt-60 usage.

Mailhot Vega R, Talcott W, Ishaq O, Cohen P, Small CJ, Duckworth T, Sarria Bardales G, Perez CA, Schiff PB, Small W Jr, Harkenrider MM.

Brachytherapy. 2017 Jul - Aug;16(4):910-915. doi: 10.1016/j.brachy.2017.04.235. Epub 2017 May 15.

PMID:
28522118
7.

Adult Primary Spinal Epidural Extraosseous Ewing's Sarcoma: A Case Report and Review of the Literature.

Bustoros M, Thomas C, Frenster J, Modrek AS, Bayin NS, Snuderl M, Rosen G, Schiff PB, Placantonakis DG.

Case Rep Neurol Med. 2016;2016:1217428. doi: 10.1155/2016/1217428. Epub 2016 Aug 17.

8.

Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer.

Shin SM, Duckworth TL, Cooper BT, Curtin JP, Schiff PB, DeWyngaert JK, Lymberis SC.

Front Oncol. 2015 Sep 14;5:201. doi: 10.3389/fonc.2015.00201. eCollection 2015.

9.

Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy.

Hsu HC, Li X, Curtin JP, Goldberg JD, Schiff PB.

Front Oncol. 2015 Apr 13;5:81. doi: 10.3389/fonc.2015.00081. eCollection 2015.

10.

Radiotherapy for extensive stage small-cell lung cancer.

Golden EB, Shin SM, Schiff PB, Formenti SC.

Lancet. 2015 Apr 4;385(9975):1290-1. doi: 10.1016/S0140-6736(15)60675-4. No abstract available.

PMID:
25890907
11.

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC.

Cancer Immunol Res. 2013 Dec;1(6):365-72. doi: 10.1158/2326-6066.CIR-13-0115.

12.

Taxanes as radiosensitizers.

Golden EB, Formenti SC, Schiff PB.

Anticancer Drugs. 2014 May;25(5):502-11. doi: 10.1097/CAD.0000000000000055. Review.

PMID:
24335716
13.

Detection of volatile biomarkers of therapeutic radiation in breath.

Phillips M, Byrnes R, Cataneo RN, Chaturvedi A, Kaplan PD, Libardoni M, Mehta V, Mundada M, Patel U, Ramakrishna N, Schiff PB, Zhang X.

J Breath Res. 2013 Sep;7(3):036002. doi: 10.1088/1752-7155/7/3/036002. Epub 2013 Jun 24.

PMID:
23793046
14.

Is there a role for an external beam boost in cervical cancer radiotherapy?

Sethi RA, Jozsef G, Grew D, Marciscano A, Pennell R, Babcock M, McCarthy A, Curtin J, Schiff PB.

Front Oncol. 2013 Jan 30;3:3. doi: 10.3389/fonc.2013.00003. eCollection 2013.

15.

Albendazole sensitizes cancer cells to ionizing radiation.

Patel K, Doudican NA, Schiff PB, Orlow SJ.

Radiat Oncol. 2011 Nov 17;6:160. doi: 10.1186/1748-717X-6-160.

16.

Modification of shirt buttons for retrospective radiation dosimetry after a radiological event.

Marino SA, Johnson GW, Schiff PB, Brenner DJ.

Health Phys. 2011 May;100(5):542-7. doi: 10.1097/HP.0b013e31820153d4.

17.

Quantitative ultrasonic evaluation of radiation-induced late tissue toxicity: pilot study of breast cancer radiotherapy.

Liu T, Zhou J, Yoshida EJ, Woodhouse SA, Schiff PB, Wang TJ, Lu ZF, Pile-Spellman E, Zhang P, Kutcher GJ.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):811-20. doi: 10.1016/j.ijrobp.2009.08.071. Epub 2010 Feb 19.

18.

A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard.

Liu T, Mansukhani MM, Benson MC, Ennis R, Yoshida E, Schiff PB, Zhang P, Zhou J, Kutcher GJ.

Med Phys. 2009 Aug;36(8):3504-11.

19.

Fertility preservation in young women with epithelial ovarian cancer.

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ.

Cancer. 2009 Sep 15;115(18):4118-26. doi: 10.1002/cncr.24461.

20.

Implementation and validation of an ultrasonic tissue characterization technique for quantitative assessment of normal-tissue toxicity in radiation therapy.

Zhou J, Zhang P, Osterman KS, Woodhouse SA, Schiff PB, Yoshida EJ, Lu ZF, Pile-Spellman ER, Kutcher GJ, Liu T.

Med Phys. 2009 May;36(5):1643-50.

21.

Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time.

Wright JD, Fiorelli J, Schiff PB, Burke WM, Kansler AL, Cohen CJ, Herzog TJ.

Cancer. 2009 Mar 15;115(6):1276-85. doi: 10.1002/cncr.24160.

22.

Safety of ovarian preservation in premenopausal women with endometrial cancer.

Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ.

J Clin Oncol. 2009 Mar 10;27(8):1214-9. doi: 10.1200/JCO.2008.19.8150. Epub 2009 Jan 26.

PMID:
19171707
23.

Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation.

Wright JD, Fiorelli J, Kansler AL, Burke WM, Schiff PB, Cohen CJ, Herzog TJ.

Am J Obstet Gynecol. 2009 Apr;200(4):419.e1-7. doi: 10.1016/j.ajog.2008.11.003. Epub 2009 Jan 10.

PMID:
19136095
24.

Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.

Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, Cohen CJ, Wright JD.

Cancer. 2008 Dec 15;113(12):3298-306. doi: 10.1002/cncr.23957.

25.

Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report.

Bansal N, Cohen CJ, Shah JN, Schiff PB, Herzog TJ, Wright JD.

J Reprod Med. 2008 Sep;53(9):700-2.

PMID:
18839826
26.

Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.

Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD.

Obstet Gynecol. 2008 Jul;112(1):64-70. doi: 10.1097/AOG.0b013e318176157c.

PMID:
18591309
27.

The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma.

Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, Herzog TJ.

Am J Obstet Gynecol. 2008 Nov;199(5):536.e1-8. doi: 10.1016/j.ajog.2008.04.019. Epub 2008 Jun 3.

PMID:
18511017
28.

Measurements of Radiation-Induced Skin Changes in Breast-Cancer Radiation Therapy Using Ultrasonic Imaging.

Liu T, Zhou J, Osterman KS, Zhang P, Woodhouse SA, Schiff PB, Kutcher GJ.

Conf Proc IEEE Eng Med Biol Soc. 2008 May 27;2:718-722.

29.

Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.

Urology. 2007 Mar;69(3):541-6.

PMID:
17382161
30.

Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.

Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, Schiff PB, Mansukhani MM, Ennis RD.

J Clin Oncol. 2007 Jan 1;25(1):77-84.

PMID:
17194907
31.

Ultrasonic spectrum-analysis and neural-network classification as a basis for ultrasonic imaging to target brachytherapy of prostate cancer.

Feleppa EJ, Ennis RD, Schiff PB, Wuu CS, Kalisz A, Ketterling J, Urban S, Liu T, Fair WR, Porter CR, Gillespie JR.

Brachytherapy. 2002;1(1):48-53.

PMID:
15062187
32.

Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003.

Coleman CN, Stone HB, Alexander GA, Barcellos-Hoff MH, Bedford JS, Bristow RG, Dynlacht JR, Fuks Z, Gorelic LS, Hill RP, Joiner MC, Liu FF, McBride WH, McKenna WG, Powell SN, Robbins ME, Rockwell S, Schiff PB, Shaw EG, Siemann DW, Travis EL, Wallner PE, Wong RS, Zeman EM.

Radiat Res. 2003 Dec;160(6):729-37.

PMID:
14640790
33.

RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy.

Gewanter RM, Katz AE, Olsson CA, Benson MC, Singh A, Schiff PB, Ennis RD.

Urology. 2003 May;61(5):967-71.

PMID:
12736017
34.

3D dosimetry study of 188Re liquid balloon for intravascular brachytherapy using bang polymer gel dosemeters.

Wuu CS, Schiff PB, Maryanski M, Liu T, Borzillary S, Weinberger J.

Radiat Prot Dosimetry. 2002;99(1-4):397-400.

PMID:
12194339
35.

Postprostatectomy salvage radiation therapy for prostate cancer: impact of pathological and biochemical variables and prostate fossa biopsy.

Mosbacher MR, Schiff PB, Otoole KM, Benson MC, Olsson CA, Brody RA, Ennis RD.

Cancer J. 2002 May-Jun;8(3):242-6.

PMID:
12074323
36.

Spectrum-analysis and neural networks for imaging to detect and treat prostate cancer.

Feleppa EJ, Ennis RD, Schiff PB, Wuu CS, Kalisz A, Ketterling J, Urban S, Liu T, Fair WR, Porter CR, Gillespie JR.

Ultrason Imaging. 2001 Jul;23(3):135-46.

PMID:
11958585
37.

Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.

Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, Bagiella E, Singh A, Ennis RD.

Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1443-6.

PMID:
11121646
38.

Adjuvant radiotherapy for DCIS.

Brenner DJ, Schiff PB, Zablotska LB.

Lancet. 2000 Jun 10;355(9220):2071; author reply 2072-3. No abstract available.

PMID:
10885373
39.
40.

PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients.

Peschel RE, Robnett TJ, Hesse D, King CR, Ennis RD, Schiff PB, Wilson LD.

Int J Cancer. 2000 Feb 20;90(1):29-36.

41.

Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.

Lee N, Newhouse JH, Olsson CA, Benson MC, Petrylak DP, Schiff PB, Bagiella E, Malyszko B, Ennis RD.

Urology. 1999 Sep;54(3):490-4.

PMID:
10475360
42.

Potential decreased morbidity of interstitial brachytherapy for gynecologic malignancies using laparoscopy: A pilot study.

Choi JC, Ingenito AC, Nanda RK, Smith DH, Wuu CS, Chin LJ, Schiff PB.

Gynecol Oncol. 1999 May;73(2):210-5. Review.

PMID:
10329036
43.

Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.

Begemann M, Kashimawo SA, Lunn RM, Delohery T, Choi YJ, Kim S, Heitjan DF, Santella RM, Schiff PB, Bruce JN, Weinstein IB.

Anticancer Res. 1998 Sep-Oct;18(5A):3139-52.

PMID:
9858877
44.

A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy.

Hall EJ, Schiff PB, Hanks GE, Brenner DJ, Russo J, Chen J, Sawant SG, Pandita TK.

Cancer J Sci Am. 1998 Nov-Dec;4(6):385-9.

PMID:
9853138
45.

Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.

Begemann M, Kashimawo SA, Heitjan DF, Schiff PB, Bruce JN, Weinstein IB.

Anticancer Res. 1998 Jul-Aug;18(4A):2275-82.

PMID:
9703866
46.

Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy.

Ennis RD, Malyszko BK, Heitjan DF, Rubin MA, O'Toole KM, Schiff PB.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):511-7. Erratum in: Int J Radiat Oncol Biol Phys 1998 Sep 1;42(2):467.

PMID:
9635696
47.

Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: a proposal based on patients treated with external beam radiotherapy.

Ennis RD, Malyszko BK, Rescigno J, Whitman AE, Heitjan DF, O'Toole KM, Rubin M, Schiff PB.

Urology. 1998 Feb;51(2):265-70.

PMID:
9495709
48.

Pulsed-dose-rate brachytherapy: design of convenient (daytime-only) schedules.

Brenner DJ, Schiff PB, Huang Y, Hall EJ.

Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):809-15.

PMID:
9369127
49.

Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer.

Ingenito AC, Ennis RD, Hsu IC, Begg MD, Benson MC, Schiff PB.

Urology. 1997 Jul;50(1):73-8.

PMID:
9218022
50.

Supplemental Content

Loading ...
Support Center